Mometasone Furoate Market - Top Companies and Manufacturers

  • Report ID: 5507
  • Published Date: May 07, 2024
  • Report Format: PDF, PPT

Companies Dominating the Mometasone Furoate Landscape

top-features-companies
    • Perrigo Company plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • Glenmark Pharmaceuticals Limited
    • Vetoquinol USA
    • AstraZeneca plc
    • Intersect ENT
    • Hikma Pharmaceuticals
    • Medlab Pharmaceuticals Private Limited
    • AdvaCare Pharma
    • Dermocare Laboratories

Browse Key Market Insights with Data Illustration:

In the News

  • Glenmark Pharmaceuticals Limited- The world-renowned, research-driven pharmaceutical business has announced the introduction of Ryaltris-AZ Nasal Spray in India for the management of moderate to severe allergic rhinitis.
     
  • Intersect ENT- a MedTech leader revolutionizing patient care, announced that it has entered into a final agreement to purchase all of the outstanding shares of Medtronic plc, a global leader in medical technology.

Author Credits:  Rajrani Baghel


  • Report ID: 5507
  • Published Date: May 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of the mometasone furoate market was over USD 1 billion.

The market size for the mometasone furoate market is projected to cross USD 3 billion by the end of 2036 expanding at a CAGR of 7% during the forecast period i.e., between 2024 and 2036.

The major players in the market are Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Hikma Pharmaceuticals, Medlab Pharmaceuticals Private Limited, AdvaCare Pharma, Dermocare Laboratories, Taro Pharmaceutical Industries Ltd., Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals., and others.

In terms of route of administration, the topical segment is anticipated to account for the largest market share of 42% during 2024-2036.

The North American mometasone furoate market is poised to hold the highest share of 47% by 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying